Mahi Drugs Profile
Key Indicators
- Authorised Capital ₹ 7.50 Cr
as on 15-11-2024
- Paid Up Capital ₹ 7.07 Cr
as on 15-11-2024
- Company Age 12 Year, 2 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 28.68 Cr
as on 15-11-2024
- Satisfied Charges ₹ 5.15 Cr
as on 15-11-2024
- Revenue 9.49%
(FY 2023)
- Profit -162.41%
(FY 2023)
- Ebitda 27.56%
(FY 2023)
- Net Worth 28.79%
(FY 2023)
- Total Assets 21.21%
(FY 2023)
About Mahi Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 Cr and a paid-up capital of Rs 7.07 Cr.
The company currently has active open charges totaling ₹28.68 Cr. The company has closed loans amounting to ₹5.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
Veeravenkata Talluri, Madhu Maganty, Venkata Talluri, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233AP2012PTC084875
- Company No.
084875
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Dec 2012
- Date of AGM
23 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mahi Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Talluri  | Managing Director | 25-Jul-2020 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sarath Pakalapati | Director | 09-Aug-2022 | Current |
| Veeravenkata Talluri | Director | 07-Apr-2018 | Current |
| Madhu Maganty | Nominee Director | 28-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Mahi Drugs.
Mahi Drugs Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.49% increase. The company also saw a substantial fall in profitability, with a 162.41% decrease in profit. The company's net worth Soared by an impressive increase of 28.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mahi Drugs?
In 2023, Mahi Drugs had a promoter holding of 60.00% and a public holding of 40.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sms Lifesciences India LimitedActive 18 years 6 monthsVeeravenkata Talluri, Venkata Talluri and 1 more are mutual person
- Shreyas Management And Services Private LimitedActive 32 years 10 months
Sarath Pakalapati is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 Aug 2020 | ₹1.92 Cr | Open |
Others Creation Date: 20 Jul 2019 | ₹7.50 Cr | Open |
Others Creation Date: 21 Jun 2019 | ₹19.26 Cr | Open |
How Many Employees Work at Mahi Drugs?
Mahi Drugs has a workforce of 201 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mahi Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mahi Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
